Search for a gene expression signature of breast cancer local recurrence in young women

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1704-1715

  Servant, Nicolas ^a,b,d   Bollet, Marc A ^a   Halfwerk, Hans ^f,g   Bleakley, Kevin ^a,b,d,e   Kreike, Bas ^g,h   Jacob, Laurent ^a,b,d,i   Sie, Daoud ^f   Kerkhoven, Ron M ^f   Hupé, Philippe ^a,b,c,d   Hadhri, Rim ^j   Fourquet, Alain ^a   Bartelink, Harry ^f   Barillot, Emmanuel ^a,b,d   Sigal Zafrani, Brigitte ^a   Van De Vijver, Marc J ^f,g  

^a INSTITUT CURIE   (France)

^b INSERM U900   (France)

^c CNRS   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e INRIA   (France)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g Neurochirurgisch Centrum Amsterdam   (Netherlands)

^h Institute for Radiation Oncology Arnhem   (Netherlands)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGE; ARTICLE; AURKA GENE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLASSIFICATION ALGORITHM; CLASSIFIER; DUTCH; ERBB2 GENE; ESR1 GENE; ESTROGEN RECEPTOR GENE; ETHNIC GROUP; FEMALE; FRENCH LANGUAGE; GENE; GENE EXPRESSION PROFILING; HER2 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PATIENT CODING; POSTOPERATIVE RADIOTHERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGESTERONE RECEPTOR GENE; RADIOTHERAPY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; TRIPLE NEGATIVE BREAST CANCER;

ADULT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS; RECURRENCE; VALIDATION STUDIES AS TOPIC;

EID: 84858253707     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1954     Document Type: Article

References (48)

1. Temple WJ, Russell ML, Parsons LL, Huber SM, Jones CA, Bankes J, et al. Conservation surgery for breast cancer as the preferred choice: a prospective analysis. J Clin Oncol 2006;24:3367-73. (Pubitemid 46638891)
2. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106. (Pubitemid 41797643)
3. Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Hölzel D. Quality of life following breast-conserving therapy or mastectomy: results of a 5- year prospective study. Breast J 2004;10:223-31. (Pubitemid 38715739)
4. Moyer A. Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. Health Psychol 1997;16: 284-98. (Pubitemid 127465968)
5. Vrieling C,Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer 2003;39:932-44. (Pubitemid 36428625)
6. Haffty BG, Carter D, Flynn SD, Fischer DB, Brash DE, Simons J, et al. Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys 1993;27:575-83. (Pubitemid 23331124)
7. Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, et al. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res 2006;12:5705-12. (Pubitemid 44629599)
8. Nuyten DSA, Kreike B, Hart AAM, Chi JA, Sneddon JB, Wessels LFA, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006;8:R62.
9. Niméus-Malmström E, Krogh M, Malmström P, Strand C, Fredriksson I, Karlsson P, et al. Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. Breast Cancer Res 2008;10:R34.
10. Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 2009;15:4181-90.
11. Balaton AL, Coindre JM, Collin F, Ettore F, Fiche M, Jacquemier J, et al. [Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/ French Association for Quality Assurance in Pathology]. Ann Pathol 1996;16:144-8.
12. Escofier B, Pagès J. Multiple factor analysis. Comput Stat Data Anal 1990;18:121-40.
13. Lê HF. FactoMineR: an R package for multivariate analysis. J Stat Software 2008;25:1-18.
14. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13. (Pubitemid 350134889)
15. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043-8. (Pubitemid 44325930)
16. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2:E7.
17. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005;102:3738-43. (Pubitemid 40354681)
18. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006;3:e47.
19. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A 2004;101:1714-9. (Pubitemid 38234220)
20. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-26. (Pubitemid 46143225)
21. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6. (Pubitemid 34130608)
22. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-5. (Pubitemid 41420886)
23. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
24. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet 2005;365:671-9. (Pubitemid 40260888)
25. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007;104:7564-9. (Pubitemid 47185946)
26. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72. (Pubitemid 43264710)
27. Starmans MH, Krishnapuram B, Steck H, Horlings H, Nuyten DS, van de Vijver MJ, et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 2008;99:1884-90.
28. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 2006;7:96.
29. Teschendorff AE, Naderi A, Barbosa-Morais NL, Pinder SE, Ellis IO, Aparicio S, et al. A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol 2006;7:R101.
30. van Vliet MH, Reyal F, Horlings HM, van de Vijver MJ, Reinders MJ, Wessels LFA. Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genom 2008;9:375.
31. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006;6:99-106. (Pubitemid 43361542)
32. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10:R65.
33. Molinaro AM, Simon R, Pfeiffer RM. Prediction error estimation: a comparison of resampling methods. Bioinformatics 2005;21:3301-7. (Pubitemid 41418445)
34. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008;24:1547-8. (Pubitemid 351911712)
35. Servant N, Gravier E, Gestraud P, Laurent C, Paccard C, Biton A, et al. EMA-a R package for Easy Microarray data analysis.BMCRes Notes 2010;3:277.
36. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
37. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-91.
38. Bollet MA, Servant N, Neuvial P, Decraene C, Lebigot I, Meyniel JP, et al. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. J Natl Cancer Inst 2008;100:48-58. (Pubitemid 351767338)
39. Schölkopf B, Smola A. Learning with kernels: support vector machines, regularization, optimization, and beyond. Cambridge, MA: MIT Press; 2002.
40. Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Annals Stat 2004;32:407-99. (Pubitemid 41250302)
41. Fourquet A, Campana F, Zafrani B, Mosseri V, Vielh P, Durand JC, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719-25. (Pubitemid 19250523)
42. Borger J, Kemperman H, Hart A, Peterse H, van Dongen J, Bartelink H. Risk factors in breast-conservation therapy. J Clin Oncol 1994;12: 653-60. (Pubitemid 24110901)
43. Elkhuizen PH, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde CJ, Leer JW. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 1998;40:859-67. (Pubitemid 28150804)
44. Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van houwelingen HC, Leer JW, et al. Risk factors for local recurrence after breastconserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys 1999;45:73-83. (Pubitemid 29380077)
45. Oh JL, Bonnen M, Outlaw ED, Schechter NR, Perkins GH, Strom EA, et al. The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: how young is "young"? Int J Radiat Oncol Biol Phys 2006;65:1345-52. (Pubitemid 44425221)
46. Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordiere A, Vincent-Salomon A, et al. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 2007;82:272-80. (Pubitemid 46350796)
47. Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DSP, Dowsett M, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010;11:339-49.
48. Kreike B, Hart AA, van de Velde T, Borger J, Peterse H, Rutgers E, et al. Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. Int J Radiat Oncol Biol Phys 2008;71:1014-21.